Seasoned international advisor will serve on the board of CureAge Therapeutics
The Children’s Tumor Foundation (CTF) and CureAge Therapeutics are pleased to announce that CTF board member Montse Montaner has joined the board of UK-based CureAge Therapeutics. CureAge is a collaborative effort between CTF and venture creator Deep Science Ventures to target the underlying genetic cause of NF1 — a genetic condition that causes tumors to grow on nerves throughout the body. NF1 affects 3 million births worldwide and can cause debilitating pain, disfigurement, and blindness.
“I am honored to join this effort at such a pivotal time in NF research,” said Montaner. “Right now, the best NF1 patients can expect is symptom management. CureAge brings together world-class experts to pinpoint the underlying cause of NF1 — and develop a life-changing treatment.”
Montaner is a visionary strategic advisor with over three decades of experience in the global pharmaceutical industry. The former chief quality officer and first chief sustainability officer of Novartis, she’s led high-performance teams across a variety of therapeutic areas, including cell and gene therapy, biologics, vaccines, and medical devices. Sustainability Magazine named her one of the top 20 women in sustainability globally in 2022 and 2023 — and she currently serves on the boards of Denmark-based biotech Bavarian Nordic and biotech validation services firm Ellab.
“We are delighted to welcome Montse to the CureAge board,” said Dr. Gonzalo Fernández-Miranda, CEO and co-founder of CureAge. “This first-of-its-kind biotech has ambitious goals — from drastically changing patient outcomes to applying findings to other peripheral nerve disorders. Montse is the perfect addition to the team.”
CureAge aims to leverage lipid nanoparticles to precisely deliver therapeutic genetic material to Schwann cells, the key cells involved in NF1 tumor growth. The company is actively seeking investors and partners to pursue its game-changing genetic therapy platform — and bring treatments to patients on a global scale.
For more information about the Children’s Tumor Foundation, visit www.ctf.org. To learn more about CureAge Therapeutics, visit www.cureagetx.com.
